<html><body><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5525">international conference</a></span> on harmonisation of technical requirements for registration of pharmaceuticals for human use   ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>   evaluation for stability data q1e   current step 4 version dated 6 february 2003          this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> has been developed by the appropriate ich expert <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4543">working</a></span> group and has been subject to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span> by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties, in accordance with the ich process.  at step 4 of the process the final draft is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for adoption to the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/665"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/909"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4054"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4060">european</a></span></a></span></a></span> union</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1524">japan</a></span> and usa. q1e <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/486"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/494">document</a></span></a></span> history  first codification history date new codification november 2005 q1e <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 2 and release for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2859">public</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532">consultation</a></span>. 6 february 2002 q1e current step 4 version q1e <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approval</a></span> by the steering committee under step 4 and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommendation</a></span> for adoption to the three ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> bodies. 6 february 2003 q1e       ii evaluation for stability data ich harmonised tripartite <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> having reached step 4 of the ich process at the ich steering committee meeting  on 6 february 2003, this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> for  adoption to the three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> parties to ich  table of contents  1. introduction....................................................................................................1 1.1 objectives of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>........................................................................................1 1.2 background.................................................................................................................1 1.3 scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>................................................................................................1 2. guidelines..........................................................................................................1 2.1 general principles......................................................................................................1 2.2 data presentation......................................................................................................3 2.3 extrapolation..............................................................................................................3 2.4 data evaluation for retest period or shelf life estimation for drug  substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for room temperature <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>.........................3 2.4.1 no significant change at accelerated condition........................................................3 2.4.2 significant change at accelerated condition.............................................................5 2.5 data evaluation for retest period or shelf life estimation for drug  substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below room temperature..............5 2.5.1 drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a refrigerator.......................5 2.5.2 drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>...............................6 2.5.3 drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c..............................7 2.6 general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches.................................................................................7 3. appendices.........................................................................................................8 appendix a: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> for data evaluation for retest period or shelf life estimation for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (excluding frozen <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>).........................8 appendix b:  examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches to stability data analysis.....................8   i evaluation of stability data  1. introduction 1.1 objectives of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is intended to provide recommendations on how to use stability data generated in accordance with the principles detailed in the ich <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> ﬁq1a(r) stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> of new drug substances and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span> (hereafter referred to as the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>) to propose a retest period or shelf life in a registration application. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> describes when and how extrapolation can be considered when 
proposing a retest period for a drug substance or a shelf life for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> that extends beyond the period covered by ﬁavailable data from the stability study under the long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditionﬂ (hereafter referred to as long-term data). 1.2 background the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> on the evaluation and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis of stability data provided in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is brief in nature and limited in scope. the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">states</a></span> that regression analysis is an appropriate approach to analyzing quantitative stability data for retest period or shelf life estimation and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommends</a></span> that a 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> for batch poolability be performed using a level of significance of 0.25. however, the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> includes few details and does not cover situations where multiple factors are involved in a full- or reduced-design study. this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> is an expansion of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> presented in the evaluation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> of the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. 1.3 scope of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> addresses the evaluation of stability data that should be submitted in registration applications for new molecular entities and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">associated</a></span> drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> provides recommendations on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> retest periods and shelf lives for 
drug substances and drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at or below ﬁroom temperatureﬂ*. it covers stability studies using single- or multi-factor designs and full or reduced designs. *note: the term ﬁroom temperatureﬂ refers to the general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/502"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6010">customary</a></span></a></span> environment and should not be inferred to be the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">statement</a></span> for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeling</a></span>. ich q6a and q6b should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5532"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5535">consulted</a></span></a></span> for recommendations on the setting and justification of acceptance criteria, and ich q1d should be referenced for recommendations on the use of full- versus reduced-design studies. 2. guidelines 2.1 general principles  the design and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5080">execution</a></span> of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies should follow the principles outlined in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. the purpose of a stability study is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span>, based on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> a minimum of three batches of the drug substance or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>, a retest period or shelf life and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> instructions applicable to all future batches 
manufactured and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> under similar circumstances. the degree of variability of individual batches affects the confidence that a future <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">production</a></span></a></span> batch will remain within acceptance criteria throughout its retest period or shelf life. 1 evaluation of stability data  2 although normal manufacturing and analytical variations are to be expected, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1309">important</a></span> that the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> be formulated with the intent to provide 100 percent of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">labeled</a></span> amount of the drug substance at the time of batch release. if the assay values of the batches used to support the registration application are higher than 100 percent of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5559">claim</a></span> at the time of batch release, after taking into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> manufacturing and analytical variations, the shelf life proposed in the application can be overestimated. on the other hand, if the assay value of a batch is lower than 100 
percent of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5559">claim</a></span> at the time of batch release, it might fall below the lower acceptance criterion before the end of the proposed shelf life. a systematic approach should be adopted in the presentation and evaluation of the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span>. the stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> should include, as appropriate, results from the physical, chemical, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4921">biological</a></span>, and microbiological <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, including those related to particular attributes of the dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> (for example, dissolution rate for solid oral dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>). the adequacy of the mass balance should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span>. factors that can cause an apparent lack of mass balance should be considered, including, for example, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1848">mechanisms</a></span> of degradation and the stability-indicating capability and inherent variability of the analytical procedures. the basic concepts of stability data evaluation are the same for single- versus multi-
factor studies and for full- versus reduced-design studies. data from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies and, as appropriate, supporting data should be evaluated to determine the critical quality attributes likely to influence the quality and performance of the drug substance or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>. each attribute should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> separately, and an overall <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> should be made of the findings for the purpose of proposing a retest period or shelf life. the retest period or shelf life proposed should not exceed that predicted for any single attribute. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> in appendix a outlines a stepwise approach to stability data evaluation and when and how much extrapolation can be considered for a proposed retest period or shelf life. appendix b provides (1) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> on how to analyze long-term data for appropriate quantitative <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> attributes from a study with a multi-factor, full or reduced design, (2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> on how to use regression analysis for retest period or shelf life estimation, and (3) examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> procedures to determine poolability of data from different batches or other factors. additional <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> can be found in the references listed; however, the examples and references do not cover all applicable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches. in general, certain quantitative chemical attributes (e.g., assay, degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/463">preservative</a></span> content) for a drug substance or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> can be assumed to follow zero-order kinetics during long-term <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage1</a></span>. data for these attributes are therefore amenable to the type of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis described in appendix b, including linear regression and poolability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span>. although the kinetics of other quantitative attributes (e.g., ph, dissolution) is  generally not known, the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis can be applied, if appropriate. qualitative attributes and microbiological attributes 
are not amenable to this kind of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis. the recommendations on <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span> are not intended to imply that use of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> evaluation is preferred when it can be justified to be 
unnecessary. however, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis can be useful in supporting the extrapolation of retest periods or shelf lives in certain situations and can be called for to verify the proposed retest periods or shelf lives in other cases. evaluation of stability data  3 2.2 data presentation data for all attributes should be presented in an appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">format</a></span> (e.g., tabular, graphical, narrative) and an evaluation of such data should be included in the 
application. the values of quantitative attributes at all time points should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2891">reported</a></span> as measured (e.g., assay as percent of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5559">claim</a></span>). if a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis is 
performed, the procedure used and the assumptions underlying the model should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span> and justified. a tabulated summary of the outcome of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and/or graphical presentation of the long-term data should be included. 2.3 extrapolation  extrapolation is the practice of using a known data set to infer <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1422">information</a></span> about future data. extrapolation to extend the retest period or shelf life beyond the period covered by long-term data can be proposed in the application, particularly if no significant change is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> at the accelerated condition. whether extrapolation of stability data is appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depends</a></span> on the extent of knowledge about the change pattern, the goodness of fit of any <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1835">mathematical</a></span> model, and the existence of relevant supporting data. any extrapolation should be performed such that the extended retest period or shelf life will be valid for a future batch released with <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> results close to the release acceptance criteria. an extrapolation of stability data assumes that the same change pattern will continue to apply beyond the period covered by long-term data. the correctness of the assumed change pattern is critical when extrapolation is considered. when estimating a regression line or curve to fit the long-term data, the data themselves provide a check on the correctness of the assumed change pattern, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> methods</a></span> can be applied to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the goodness of fit of the data to the assumed line or curve. no such internal check is possible beyond the period covered by long-term data. thus, a retest period or shelf life granted on the basis of extrapolation should always be verified by additional long-term stability data as soon as these data become available. care should be taken to include in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6884">protocol</a></span> for commitment batches a time point that <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponds</a></span> to the end of the extrapolated retest period or shelf life. 2.4 data evaluation for retest period or shelf life estimation for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for room temperature <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> a systematic evaluation of the data from <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability studies should be performed as illustrated in this <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span>. stability data for each attribute should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> sequentially. for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> at room temperature, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessment</a></span> should begin with any significant change at the accelerated condition and, if appropriate, at the intermediate condition, and progress through the trends and variability of the long-term data. the circumstances are delineated under which extrapolation of retest period or shelf life beyond the period covered by long-term data can be appropriate. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> is provided in appendix a as an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5172">aid</a></span>. 2.4.1 no significant change at accelerated condition  where no significant change occurs at the accelerated condition, the retest period or shelf life would <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the nature of the long-term and accelerated data. evaluation of stability data  4 2.4.1.1 long-term and accelerated data showing little or no change over time and little or no variability where the long-term data and accelerated data for an attribute show little or no change over time and little or no variability, it might be apparent that the drug substance or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> will remain well within the acceptance criteria for that attribute during the proposed retest period or shelf life. in these circumstances, a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> 
analysis is normally considered unnecessary but justification for the omission should be provided. justification can include a discussion of the change pattern or lack of change, relevance of the accelerated data, mass balance, and/or other supporting data as described in the parent <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guideline</a></span>. extrapolation of the retest period or shelf life beyond the period covered by long-term data can be proposed. the proposed retest period or shelf life can be up to twice, but should not be more than 12 months beyond, the period covered by long-term data. 2.4.1.2 long-term or accelerated data showing change over time and/or variability if the long-term or accelerated data for an attribute show change over time and/or variability within a factor or among factors, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis of the long-term data can be useful in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> a retest period or shelf life.  where there are differences in stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5756"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6264">observed</a></span></a></span> among batches or among other factors (e.g., strength, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or fill) or factor combinations (e.g., strength-by-<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or fill) that preclude the combining of data, the proposed retest period or shelf life should not 
exceed the shortest period supported by any batch, other factor, or factor combination.  
alternatively, where the differences are readily attributed to a particular factor (e.g., strength), different shelf lives can be assigned to different levels within the factor (e.g., different strengths). a discussion should be provided to address the cause for the 
differences and the overall significance of such differences on the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  extrapolation beyond the period covered by long-term data can be proposed; however, the extent of extrapolation would <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on whether long-term data for the attribute are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis.  data not amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis  where long-term data are not amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis, but relevant supporting data are provided, the proposed retest period or shelf life can be up to one-and-a-half times, but should not be more than 6 months beyond, the period covered by long-term data. relevant supporting data include satisfactory long-term data from development batches that are (1) made with a closely related formulation to, (2) manufactured on a smaller scale than, or (3) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> closure system similar to, that of the primary stability batches.  data amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis if long-term data are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis but no analysis is performed, the extent of extrapolation should be the same as when data are not amenable to 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis. however, if a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis is performed, it can be appropriate to propose a retest period or shelf life of up to twice, but not more than 12 months beyond, the period covered by long-term data, when the proposal is backed by the result of the analysis and relevant supporting data. evaluation of stability data  5 2.4.2 significant change at accelerated condition where significant change* occurs at the accelerated condition, the retest period or shelf life would <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on the outcome of stability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate 
condition, as well as at the long-term condition. *note: the following physical changes can be expected to occur at the accelerated condition and would not be considered significant change that calls for intermediate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> if there is no other significant change:  softening of a suppository that is designed to melt at 37ºc, if the melting point is 
clearly demonstrated,  failure to meet acceptance criteria for dissolution for 12 units of a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6787">gelatin</a></span> capsule or gel-coated tablet if the failure can be unequivocally attributed to cross-linking. however, if phase separation of a semi-solid dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> occurs at the accelerated condition, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the intermediate condition should be performed. potential <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> effects should also be considered in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> that there is no other significant change. 2.4.2.1 no significant change at intermediate condition if there is no significant change at the intermediate condition, extrapolation beyond the period covered by long-term data can be proposed; however, the extent of extrapolation would <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5390">depend</a></span> on whether long-term data for the attribute are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis.  data not amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis when the long-term data for an attribute are not amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis, the proposed retest period or shelf life can be up to 3 months beyond the period covered by long-term data, if backed by relevant supporting data.  data amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis when the long-term data for an attribute are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis but no analysis is performed, the extent of extrapolation should be the same as when data are not amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis. however, if a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis is performed, the proposed retest period or shelf life can be up to one-and-half times, but should not be more than 6 months beyond, the period covered by long-term data, when backed by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and relevant supporting data. 2.4.2.2 significant change at intermediate condition   where significant change occurs at the intermediate condition, the proposed retest period or shelf life should not exceed the period covered by long-term data.  in addition, a retest period or shelf life shorter than the period covered by long-term data 
could be called for. 2.5 data evaluation for retest period or shelf life estimation for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below room temperature 2.5.1 drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a refrigerator  data from drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended to be stored in a refrigerator should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> according to the same principles as described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.4 for drug evaluation of stability data  6 substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for room temperature <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span>, except where explicitly noted in the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> below. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> in appendix a can be used as an <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5172">aid</a></span>. 2.5.1.1 no significant change at accelerated condition where no significant change occurs at the accelerated condition, extrapolation of 
retest period or shelf life beyond the period covered by long-term data can be proposed based on the principles outlined in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> 2.4.1, except that the extent of extrapolation should be more limited. if the long-term and accelerated data show little change over time and little variability, the proposed retest period or shelf life can be up to one-and-a-half times, but should not be more than 6 months beyond, the period covered by long-term data normally without the support of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis. where the long-term or accelerated data show change over time and/or variability, the proposed retest period or shelf life can be up to 3 months beyond the period covered by long-term data if (1) the long-term data are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis but a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis is not performed, or (2) the long-term data are not amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis but relevant supporting data are provided. where the long-term or accelerated data show change over time and/or variability, the proposed retest period or shelf life can be up to one-and-a-half times, but should not be more than 6 months beyond, the period covered by long-term data if (1) the long-term data are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis is performed, and (2) the proposal is backed by the result of the analysis and relevant supporting data. 2.5.1.2 significant change at accelerated condition if significant change occurs between 3 and 6 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, the proposed retest period or shelf life should be based on the long-term data. extrapolation is not considered appropriate. in addition, a retest period or shelf life shorter than the period covered by long-term data could be called for. if the long-term data show variability, verification of the proposed retest period or shelf life by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis can be appropriate. if significant change occurs within the first 3 months™ <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> at the accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition, the proposed retest period or shelf life should be based on long-term data. extrapolation is not considered appropriate. a retest period or shelf life shorter than the period covered by long-term data could be called for. if the long-term data show variability, verification of the proposed retest period or shelf life by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis can be appropriate. in addition, a discussion should be provided to address the effect of short-term excursions outside the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition (e.g., during shipping or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>). this discussion can be supported, if appropriate, by further 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch of the drug substance or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> at the accelerated condition 
for a period shorter than 3 months. 2.5.2 drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span> for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, the retest period or shelf life should be based on long-term data. in the absence of an accelerated <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> 
condition for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended to be stored in a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/109">freezer</a></span>, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> on a single batch at an elevated temperature (e.g., 5°c ± 3°c or 25°c ± 2°c) for an evaluation of stability data  7 appropriate time period should be conducted to address the effect of short-term excursions outside the proposed <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> condition (e.g., during shipping or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3629">handling</a></span>). 2.5.3 drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c  for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> intended for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> below -20°c, the retest period or shelf life should be based on long-term data and should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessed</a></span> on a case-by-case 
basis. 2.6 general <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches  where applicable, an appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> method</a></span> should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to analyze the long-term primary stability data in an original application. the purpose of this analysis is to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establish</a></span>, with a high degree of confidence, a retest period or shelf life 
during which a quantitative attribute will remain within acceptance criteria for all future batches manufactured, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span>, and stored under similar circumstances.  in cases where a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis was <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to evaluate long-term data due to a change over time and/or variability, the same <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> method</a></span> should also be used to analyse data from commitment batches to verify or extend the originally <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1252">approved</a></span> retest period or shelf life. regression analysis is considered an appropriate approach to evaluating the stability data for a quantitative attribute and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/871">establishing</a></span> a retest period or shelf life.  the nature of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> between an attribute and time will determine whether data 
should be transformed for linear regression analysis. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> can be represented by a linear or non-linear function on an arithmetic or logarithmic scale. in some cases, a non-linear regression can better reflect the true <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span>. an appropriate approach to retest period or shelf life estimation is to analyze a 
quantitative attribute (e.g., assay, degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>) by determining the earliest time at which the 95 percent confidence limit for the mean intersects the proposed acceptance criterion. for an attribute known to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/364">decrease</a></span> with time, the lower one-sided 95 percent 
confidence limit should be compared to the acceptance criterion. for an attribute known to increase with time, the upper one-sided 95 percent confidence limit should 
be compared to the acceptance criterion. for an attribute that can either increase or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/364">decrease</a></span>, or whose <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/448">direction</a></span> of change is not known, two-sided 95 percent confidence limits should be calculated and compared to the upper and lower acceptance criteria. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> method</a></span> used for data analysis should take into <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/54"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/60"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/61">account</a></span></a></span></a></span> the stability study design to provide a valid <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> inference for the estimated retest period or shelf life. the approach described above can be used to estimate the retest period or 
shelf life for a single batch or for multiple batches when the data are combined after an appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span>. examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches to the analysis of 
stability data from single or multi-factor, full- or reduced-design studies are included in appendix b.  references to current <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1680">literature</a></span> sources can be found in appendix b.6. evaluation of stability data  3. appendices appendix a: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/348">decision</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2404">tree</a></span> for data evaluation for retest period or shelf life estimation for drug substances or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span> (excluding frozen <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>)  no  significant change at accelerated condition within 3  months? yes no extrapolation;shorterretest period or shelf life and data covering excursions can be called for; <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis if long-term data show variability     tabulate and/or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2237">plot</a></span> stability data on all attributes at all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4291">storage</a></span> conditions and evaluate each attribute separately    8     significant change at accelerated condition within  6 months? yes  intended to be stored in a refrigerator? no no yes to both y= up to 2x, but not exceeding x + 12 months;  or if refrigerated, y = up to 1.5x, but not  exceeding x + 6 months yes no extrapolation; shorterretest period or shelf life can be called for; <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis if long-term data show variability no to (1) or(2)if backed by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and relevant supporting data: y = up to 2x, but not exceeding x + 12 months; or if refrigerated, y = up to 1.5x, but not exceeding x + 6 months  no to (1)  or (2) if backed by relevant supporting data: y = up to x + 3 months (1)long- term data amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and (2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis performed?no to (1) or  (2) or both no to (1) or (2) or both long- term data show: (1) little or no change over time and (2) little or no variability? accelerated data show: (1) little or no  change over time and (2) little or no variability? <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis is normally unnecessary yes to both (1)long-termdata amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and (2) <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis performed? significant change at intermediatecondition? yes no yestobothif backed by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis and relevant supporting data: y = up to 1.5x, but not exceeding x + 6 months yes to both y = proposed retest period or shelf lifex = period covered by long-term data if backed by relevant supporting data: y = up to 1.5x, but  not exceeding x + 6 months; or if refrigerated, y = up to x + 3  months  evaluation of stability data  9 appendix b:  examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches to stability data analysis linear regression, poolability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span>, and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> modeling, described below, are examples of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1895"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> methods</a></span> and procedures that can be used in the analysis of stability data that are amenable to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis for a quantitative attribute for which there is a proposed acceptance criterion. b.1 data analysis for a single batch in general, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2239">relationship</a></span> between certain quantitative attributes and time is assumed to be linear1. figure 1 shows the regression line for assay of a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with upper and lower acceptance criteria of 105 percent and 95 percent of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5559">claim</a></span>, respectively, with 12 months of long-term data and a proposed shelf life of 24 months.  in this example, two-sided 95 percent confidence limits for the mean are applied because it is not known ahead of time whether the assay would increase or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/364">decrease</a></span> with time (e.g., in the case of an aqueous-based <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaged</a></span> in a semi-permeable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span>). the lower confidence limit intersects the lower acceptance criterion at 30 months, while the upper confidence limit does not intersect with the upper acceptance criterion until later.  therefore, the proposed shelf life of 24 months can be supported by the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis of the assay, provided the recommendations in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> 2.4 and 2.5 are followed. when data for an attribute with only an upper or a lower acceptance criterion are analyzed, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/242">corresponding</a></span> one-sided 95 percent confidence limit for the mean is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span>.  figure 2 shows the regression line for a degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> in a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> with 12 months of long-term data and a proposed shelf life of 24 months, where the acceptance criterion is not more than 1.4 percent. the upper one-sided 95 percent confidence limit for the mean intersects the acceptance criterion at 31 months.  therefore, the proposed shelf life of 24 months can be supported by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis of the degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> data, provided the recommendations in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> 2.4 and 2.5 are followed.  if the above approach is used, the mean value of the quantitative attribute (e.g., 
assay, degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">products</a></span></a></span>) can be expected to remain within the acceptance criteria through the end of the retest period or shelf life at a confidence level of 95 percent. the approach described above can be used to estimate the retest period or shelf life for a single batch, individual batches, or multiple batches when combined after appropriate <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> b.2 through b.5. b.2 data analysis for one-factor, full-design studies for a drug substance or for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> available in a single strength and a single <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> size and/or fill, the retest period or shelf life is generally estimated based on 
the stability data from a minimum of three batches. when analyzing data from such one-factor, batch-only, full-design studies, two <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> approaches can be considered.   the objective of the first approach is to determine whether the data from all 
batches support the proposed retest period or shelf life.   the objective of the second approach, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for poolability, is to determine whether the data from different batches can be combined for an overall estimate of a single retest period or shelf life. evaluation of stability data  10 b.2.1 evaluating whether all batches support the proposed retest period or shelf life the objective of this approach is to evaluate whether the estimated retest periods or shelf lives from all batches are longer than the one proposed. retest periods or shelf lives for individual batches should first be estimated using the procedure described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.1 with individual intercepts, individual slopes, and the pooled mean square error calculated from all batches. if each batch has an estimated retest period or shelf life longer than that proposed, the proposed retest period or shelf life will generally be considered appropriate, as long as the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> for extrapolation in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> 2.4 and 
2.5 is followed. there is generally no need to perform poolability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> or identify the most reduced model. if, however, one or more of the estimated retest periods or shelf lives are shorter than that proposed, poolability <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> can be performed to determine whether the batches can be combined to estimate a longer retest period or shelf life. alternatively, the above approach can be taken during the pooling process described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.2.2. if the regression lines for the batches are found to have a common slope and the estimated retest periods or shelf lives based on the common slope and individual intercepts are all longer than the proposed retest period or shelf life, there is generally no need to continue to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the intercepts for poolability. b.2.2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for poolability of batches b.2.2.1 analysis of covariance before pooling the data from several batches to estimate a retest period or shelf life, a preliminary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> should be performed to determine whether the regression lines from different batches have a common slope and a common time-zero intercept. analysis of covariance (ancova) can be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span>, where time is considered the covariate, to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the differences in slopes and intercepts of the regression lines among batches. each of these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> should be conducted using a significance level of 0.25 to compensate for the expected low power of the design due to the relatively limited <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">sample</a></span> size in a typical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formal</a></span> stability study. if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> rejects the hypothesis of equality of slopes (i.e., if there is a significant 
difference in slopes among batches), it is not considered appropriate to combine the data from all batches.  the retest periods or shelf lives for individual batches in the stability study can be estimated by applying the approach described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.1 using individual intercepts and individual slopes and the pooled mean square error calculated from all batches. the shortest estimate among the batches should be 
chosen as the retest period or shelf life for all batches. if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> rejects the hypothesis of equality of intercepts but fails to reject that the slopes are equal (i.e., if there is a significant difference in intercepts but no significant difference in slopes among the batches), the data can be combined for the purpose of estimating the common slope. the retest periods or shelf lives for individual batches in the stability study should be estimated by applying the approach described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.1, using the common slope and individual intercepts. the shortest estimate among the batches should be chosen as the retest period or shelf life for all batches. if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> for equality of slopes and equality of intercepts do not result in rejection at a level of significance of 0.25 (i.e., if there is no significant difference in slope and intercepts among the batches), the data from all batches can be combined.  a single retest period or shelf life can be estimated from the combined data by using the evaluation of stability data  11 approach described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.1 and applied to all batches. the estimated retest period or shelf life from the combined data is usually longer than that from individual batches because the width of the confidence limit(s) for the mean will become narrower as the amount of data increases when batches are combined. the pooling <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> described above should be performed in a proper order such that the slope terms are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> before the intercept terms. the most reduced model (i.e., 
individual slopes, common slope with individual intercepts, or common slope with common intercept, as appropriate) can be selected for retest period or shelf life estimation. b.2.2.2 other methods <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> procedures2-6 other than those described above can be used in retest period or shelf life estimation.  for example, if it is possible to decide in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4383">advance</a></span> the acceptable difference in slope or in mean retest period or shelf life among batches, an appropriate procedure for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessing</a></span> the equivalence in slope or in mean retest period 
or shelf life can be used to determine the data poolability.  however, such a procedure should be prospectively defined, evaluated, and justified and, where appropriate, discussed with the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authority.  a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulation</a></span> study can be useful, if applicable, to demonstrate that the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> properties of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> procedure selected are appropriate7. b.3 data analysis for multi-factor, full-design studies the stability of the drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> could differ to a certain degree among different factor combinations in a multi-factor, full-design study. two approaches can be considered when analyzing such data.  the objective of the first approach is to determine whether the data from all factor 
combinations support the proposed shelf life.  the objective of the second approach, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for poolability, is to determine whether the data from different factor combinations can be combined for an overall estimate of a single shelf life. b.3.1 evaluating whether all factor combinations support the proposed shelf life the objective of this approach is to evaluate whether the estimated shelf lives from all factor combinations are longer than the one proposed. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> model that includes all appropriate factors and factor combinations should be constructed as described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3.2.2.1, and the shelf life should be estimated for each level of each factor and factor combination. if all shelf lives estimated by the original model are longer than the proposed shelf life, further model <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4831">building</a></span> is considered unnecessary and the proposed shelf life will generally be appropriate as long as the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5311">guidance</a></span> in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">sections</a></span> 2.4 and 2.5 is followed. if one or more of the estimated shelf lives fall short of the proposed shelf life, model <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4831">building</a></span> as described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3.2.2.1 can be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span>. however, it is considered unnecessary to identify the final model before evaluating whether the data support the proposed shelf life. shelf lives can be estimated at each stage of the model <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4831">building</a></span> process, and if all shelf lives at any stage are longer than the one proposed, further attempts to reduce the model are considered unnecessary. evaluation of stability data  12 this approach can simplify the data analysis of a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/8417">complicated</a></span> multi-factor stability study compared to the data analysis described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3.2.2.1. b.3.2  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for poolability the stability data from different combinations of factors should not be combined unless supported by <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> for poolability. b.3.2.1 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for poolability of batch factor only if each factor combination is considered separately, the stability data can be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for poolability of batches only, and the shelf life for each non-batch factor combination can be estimated separately by applying the procedure described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.2.  for example, for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> available in two strengths and four <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes, eight sets of data from the 2x4 strength-size combinations can be analyzed and eight 
separate shelf lives should be estimated accordingly.  if a single shelf life is desired, the shortest estimated shelf life among all factor combinations should become the 
shelf life for the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span>.  however, this approach does not take advantage of the available data from all factor combinations, thus generally resulting in shorter shelf lives than does the approach in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3.2.2. b.3.2.2 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> for poolability of all factors and factor combinations if the stability data are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for poolability of all factors and factor combinations and the results show that the data can be combined, a single shelf life longer than that estimated based on individual factor combinations is generally obtainable.  the shelf life is longer because the width of the confidence limit(s) for the mean will become narrower as the amount of data increases when batches, strengths, <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes and/or fills, etc. are combined. b.3.2.2.1 analysis of covariance analysis of covariance can be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/735">employed</a></span> to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the difference in slopes and intercepts of the regression lines among factors and factor combinations7, 8. the purpose of the procedure is to determine whether data from multiple factor combinations can be 
combined for the estimation of a single shelf life. the full <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> model should include the intercept and slope terms of all main effects and <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> effects and a term reflecting the random error of measurement.  if it can be justified that the higher order <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> are very small, there is generally no need to include these terms in the model.  in cases where the analytical 
results at the initial time point are obtained from the finished dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">form</a></span> prior to its <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/720">packaging</a></span>, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> intercept term can be excluded from the full model because the results are common among the different <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes and/or fills. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> for poolability should be specified to determine whether there are 
statistically significant differences among factors and factor combinations. generally, the pooling <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> should be performed in a proper order such that the slope terms are 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> before the intercept terms and the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> effects are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> before the main effects. for example, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> can start with the slope and then the intercept terms of the highest order <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span>, and proceed to the slope and then the intercept terms of 
the simple main effects. the most reduced model, obtained when all remaining terms are found to be statistically significant, can be used to estimate the shelf lives. evaluation of stability data  13 all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> should be conducted using appropriate levels of significance. it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2926">recommended</a></span> that a significance level of 0.25 be used for batch-related terms, and a significance level of 0.05 be used for non-batch-related terms.  if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> for poolability show that the data from different factor combinations can be combined, the shelf life can be estimated according to the procedure described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.1 using the combined data. if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tests</a></span> for poolability show that the data from certain factors or factor combinations should not be combined, either of two alternatives can be applied: (1) a separate shelf life can be estimated for each level of the factors and of the factor 
combinations remaining in the model; or (2) a single shelf life can be estimated based on the shortest estimated shelf life among all levels of factors and factor combinations remaining in the model. b.3.2.2.2 other methods <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> procedures2-6 to those described above can be applied.  for example, an appropriate procedure for <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/184">assessing</a></span> the equivalence in slope or in mean shelf life can be used to determine the data poolability.  however, such a procedure should be prospectively defined, evaluated, properly justified, and, where appropriate, discussed with the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3099">regulatory</a></span> authority. a <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6267">simulation</a></span> study can be useful, if applicable, to demonstrate that the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> properties of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4328">alternative</a></span> procedure selected are appropriate7. b.4 data analysis for bracketing design studies the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> procedures described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3 can be applied to the analysis of stability data obtained from a bracketing design study.  for example, for a drug <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> available in three strengths (s1, s2, and s3) and three <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes (p1, p2, and p3) and studied according to a bracketing design where only the two <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span> of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/158">container</a></span> sizes (p1 and p3) are <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>, six sets of data from the 3x2 strength-size combinations will be obtained.  the data can be analyzed separately for each of the six combinations for shelf life estimation according to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3.2.1, or <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> for 
poolability prior to shelf life estimation according to <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3.2.2. the bracketing design assumes that the stability of the intermediate strengths or 
sizes is represented by the stability at the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extremes</a></span>.  if the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis indicates that the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extreme</a></span> strengths or sizes is different, the intermediate strengths or sizes should be considered no more stable than the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4598">least</a></span> stable <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5634">extreme</a></span>.  for example, if p1 from the above bracketing design is found to be less stable than p3, the shelf life for p2 should not exceed that for p1.  no 
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5688">interpolation</a></span> between p1 and p3 should be considered. b.5 data analysis for matrixing design studies a matrixing design has only a fraction of the total number of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> at any 
specified time point. therefore, it is <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1309">important</a></span> to ascertain that all factors and factor combinations that can have an impact on shelf life estimation have been appropriately <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span>. for a meaningful <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1482">interpretation</a></span> of the study results and shelf life estimation, certain assumptions should be made and justified. for instance, the assumption that the stability of the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">tested</a></span> represents the stability of all <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/623">samples</a></span> should be valid. in addition, if the design is not balanced, some factors or 
factor <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> might not be estimable. furthermore, for different levels of factor combinations to be poolable, it might have to be assumed that the higher order factor evaluation of stability data  14 <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> are negligible.  because it is usually impossible to statistically <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> the assumption that the higher order terms are negligible, a matrixing design should be used only when it is reasonable to assume that these <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> are indeed very small, based on supporting data. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> procedure described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3 can be applied to the analysis of stability data obtained from a matrixing design study. the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> analysis should clearly identify the procedure and assumptions used. for instance, the assumptions underlying the model in which <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interaction</a></span> terms are negligible should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span>. if a preliminary <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">test</a></span> is performed for the purpose of eliminating factor <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/6908">interactions</a></span> from the model, the procedure used should be provided and justified. the final model on which the estimation of shelf life will be based should be <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/883">stated</a></span>. the estimation of 
shelf life should be performed for each of the terms remaining in the model. the use of a matrixing design can result in an estimated shelf life shorter than that resulting from a full design. where bracketing and matrixing are combined in one design, the <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> procedure described in <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span> b.3 can be applied. b.6 references 1. carstensen, j.t., ﬁstability and dating of solid dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">formsﬂ</a></span>  pharmaceutics of solids and solid dosage <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1076">forms</a></span>, wiley-interscience, 182-185, 1977  2. ruberg, s.j. and stegeman, j.w., ﬁpooling data for stability studies: <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/867">testing</a></span> the equality of batch degradation slopesﬂ  
<span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7410">biometrics</a></span>, 47:1059-1069, 1991  3. ruberg, s.j. and hsu, j.c., ﬁmultiple comparison procedures for pooling batches in stability studiesﬂ  technometrics, 34:465-472, 1992  4. shao, j. and chow, s.c., ﬁstatistical inference in stability analysisﬂ  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/7410">biometrics</a></span>, 50:753-763, 1994  5. murphy, j.r. and weisman, d., ﬁusing random slopes for estimating shelf-lifeﬂ proceedings of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/1587">american</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4256">statistical</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2944">association</a></span> of the biopharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/3803">section</a></span>, 196-200, 1990  6. yoshioka, s., aso, y, and kojima, s., ﬁassessment of shelf-life equivalence of pharmaceutical <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">productsﬂ</a></span></a></span>  
chem. pharm. <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/4388">bull</a></span>., 45:1482-1484, 1997  7. chen, j.j., ahn, h., and tsong, y., ﬁshelf-life estimation for multifactor stability studiesﬂ  
drug inf. journal, 31:573-587, 1997  8. fairweather, w., lin, t.d., and kelly, r., ﬁregulatory, design, and analysis aspects of complex stability studiesﬂ  j. pharm. sci., 84:1322-1326, 1995 evaluation of stability data  b.7 figures figure 1   shelf life estimation with upper and lower acceptance criteria based on assay at  25c/60%rh80 85 90 95 100 105 110 115 120 0 3 6 9 12 15 18 21242730333639424548 time point (months)assay (% of <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/893">label</a></span> <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/5559">claim</a></span>) raw dataupper confidence limitlower confidence limitregression line upper acceptance criterion: 105 lower acceptance 
criterion: 95  figure 2  shelf life estimation with upper acceptance criterion based on a degradation  <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> at  25c/60%rh0.0 0.5 1.0 1.5 2.0 2.5 3.0 0 3 6 9 12 15 18 21242730333639424548 time point (months)degradation <span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2707"><span style="background-color: #FFFF00"><a href="http://eurovoc.europa.eu/2724">product</a></span></a></span> (%) raw dataupper confidence limitregression line upper acceptance criterion: 1.4  15 </body><html>